Breakdown | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 4.21B | 3.88B | 2.92B | 2.08B | 1.95B |
Gross Profit | 704.74M | 674.67M | 753.05M | 519.47M | 649.93M |
EBITDA | 737.83M | 782.26M | 807.25M | 597.19M | 624.25M |
Net Income | -18.95M | 69.65M | 197.50M | 192.87M | 286.58M |
Balance Sheet | |||||
Total Assets | 5.37B | 5.51B | 4.86B | 3.79B | 2.56B |
Cash, Cash Equivalents and Short-Term Investments | 606.32M | 726.84M | 874.07M | 938.70M | 632.35M |
Total Debt | 1.60B | 1.53B | 944.89M | 1.03B | 719.90M |
Total Liabilities | 2.97B | 3.14B | 2.51B | 2.16B | 1.39B |
Stockholders Equity | 1.96B | 1.85B | 1.88B | 1.27B | 1.00B |
Cash Flow | |||||
Free Cash Flow | 527.88M | 195.83M | 343.21M | 467.35M | 504.58M |
Operating Cash Flow | 689.10M | 608.32M | 603.48M | 616.45M | 574.37M |
Investing Cash Flow | -358.36M | -715.62M | -586.10M | -366.50M | 314.91M |
Financing Cash Flow | -486.46M | -51.31M | -80.16M | 158.62M | -735.82M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
66 Neutral | HK$746.68M | 19.67 | -8.91% | 1.59% | 169.20% | ― | |
60 Neutral | HK$16.95B | 5.65 | -7.44% | 2.87% | 11.55% | -28.15% | |
― | $135.19M | ― | -20.26% | ― | ― | ― | |
77 Outperform | HK$31.52B | 35.90 | 37.28% | 0.03% | 59.83% | 68.29% | |
67 Neutral | HK$60.81B | 25.25 | 36.16% | 1.15% | 54.44% | 35.90% | |
64 Neutral | HK$777.66M | 12.12 | 8.96% | ― | 30.72% | -35.61% | |
63 Neutral | HK$403.28M | 7.25 | 12.01% | ― | 25.55% | 14.47% |
EC Healthcare announced the completion of a significant transaction involving the disposal of 51% of the issued share capital in a target company and the acquisition of 40% of the issued share capital in a non-wholly owned subsidiary. As a result, the company no longer holds interests in the target group, and these entities will not be included in the company’s consolidated financial statements, potentially impacting its financial reporting and market positioning.
EC Healthcare, a company incorporated in the Cayman Islands, has announced a change in the Long Stop Date for its Share Purchase Agreement. Initially set for February 6, 2025, the date has been revised to February 21, 2025. The Board believes this adjustment aligns with the interests of the company and its shareholders, while all other terms of the agreement remain unchanged.
EC Healthcare announced that the resolutions proposed at its Extraordinary General Meeting (EGM) were successfully passed by shareholders. The approved resolutions included acquisition and disposal agreements, with a significant 64.1% of total shares represented at the meeting. This approval is expected to impact the company’s operational strategies and strengthen its market positioning.